Clinical effect of add-on Primovist-enhanced magnetic resonance imaging on preoperative tumor staging in hepatocellular carcinoma patients

Young Joo Jin, Jin Woo Lee, Oh Sang Kwon, Young Kul Jung, Jung Hyun Kwon, Jeong Won Jang, Young Seok Kim, Tae Hun Kim, Yong Sun Jeon

Research output: Contribution to journalArticle

Abstract

Background/Aims: We analyzed the incidence of change of Barcelona Clinic Liver Cancer (BCLC) stage after add-on Primovist-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer stage 0 or A as determined by liver dynamic computed tomography (LDCT). Methods: A total of 166 patients enrolled prospectively between August 2012 and December 2014 were retrospectively analyzed. The rates of stage change after Primovist-enhanced MRI and the treatment finally adopted in patients with stage change were evaluated. Results: Of the 166 patients, 24 (18.6%) had truly new HCCs. Forty-six (27.7%) and 120 (72.3%) patients had BCLC stages 0 and A, respectively, before Primovist-enhanced MRI, but after Primovist-enhanced MRI, 28 (16.9%), 134 (80.7%), and 4 (2.4%) patients had BCLC stages 0, A, and B, respectively. Tumor stage changed in 22 (13.3%) patients, from 0 to A (18, 39.1%) or A to B (4, 3.3%). Conclusions: Add-on Primovist-enhanced magnetic resonance imaging can change BCLC stage with 13.3% in patients with BCLC 0 or A staged HCC, as determined by LDCT. J. Surg. Oncol. 2016;114:106–111.

Original languageEnglish
Pages (from-to)106-111
Number of pages6
JournalJournal of Surgical Oncology
Volume114
Issue number1
DOIs
Publication statusPublished - 2016 Jul 1

Fingerprint

Neoplasm Staging
Hepatocellular Carcinoma
Liver Neoplasms
Magnetic Resonance Imaging
Tomography
gadolinium ethoxybenzyl DTPA
Liver
Incidence

Keywords

  • Barcelona clinic liver cancer
  • hepatocellular carcinoma
  • liver dynamic computed tomography
  • primovist-enhanced magnetic resonance imaging

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Clinical effect of add-on Primovist-enhanced magnetic resonance imaging on preoperative tumor staging in hepatocellular carcinoma patients. / Jin, Young Joo; Lee, Jin Woo; Kwon, Oh Sang; Jung, Young Kul; Kwon, Jung Hyun; Jang, Jeong Won; Kim, Young Seok; Kim, Tae Hun; Jeon, Yong Sun.

In: Journal of Surgical Oncology, Vol. 114, No. 1, 01.07.2016, p. 106-111.

Research output: Contribution to journalArticle

Jin, Young Joo ; Lee, Jin Woo ; Kwon, Oh Sang ; Jung, Young Kul ; Kwon, Jung Hyun ; Jang, Jeong Won ; Kim, Young Seok ; Kim, Tae Hun ; Jeon, Yong Sun. / Clinical effect of add-on Primovist-enhanced magnetic resonance imaging on preoperative tumor staging in hepatocellular carcinoma patients. In: Journal of Surgical Oncology. 2016 ; Vol. 114, No. 1. pp. 106-111.
@article{c3a4ccda07294739baa7866c59e62c48,
title = "Clinical effect of add-on Primovist-enhanced magnetic resonance imaging on preoperative tumor staging in hepatocellular carcinoma patients",
abstract = "Background/Aims: We analyzed the incidence of change of Barcelona Clinic Liver Cancer (BCLC) stage after add-on Primovist-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer stage 0 or A as determined by liver dynamic computed tomography (LDCT). Methods: A total of 166 patients enrolled prospectively between August 2012 and December 2014 were retrospectively analyzed. The rates of stage change after Primovist-enhanced MRI and the treatment finally adopted in patients with stage change were evaluated. Results: Of the 166 patients, 24 (18.6{\%}) had truly new HCCs. Forty-six (27.7{\%}) and 120 (72.3{\%}) patients had BCLC stages 0 and A, respectively, before Primovist-enhanced MRI, but after Primovist-enhanced MRI, 28 (16.9{\%}), 134 (80.7{\%}), and 4 (2.4{\%}) patients had BCLC stages 0, A, and B, respectively. Tumor stage changed in 22 (13.3{\%}) patients, from 0 to A (18, 39.1{\%}) or A to B (4, 3.3{\%}). Conclusions: Add-on Primovist-enhanced magnetic resonance imaging can change BCLC stage with 13.3{\%} in patients with BCLC 0 or A staged HCC, as determined by LDCT. J. Surg. Oncol. 2016;114:106–111.",
keywords = "Barcelona clinic liver cancer, hepatocellular carcinoma, liver dynamic computed tomography, primovist-enhanced magnetic resonance imaging",
author = "Jin, {Young Joo} and Lee, {Jin Woo} and Kwon, {Oh Sang} and Jung, {Young Kul} and Kwon, {Jung Hyun} and Jang, {Jeong Won} and Kim, {Young Seok} and Kim, {Tae Hun} and Jeon, {Yong Sun}",
year = "2016",
month = "7",
day = "1",
doi = "10.1002/jso.24272",
language = "English",
volume = "114",
pages = "106--111",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical effect of add-on Primovist-enhanced magnetic resonance imaging on preoperative tumor staging in hepatocellular carcinoma patients

AU - Jin, Young Joo

AU - Lee, Jin Woo

AU - Kwon, Oh Sang

AU - Jung, Young Kul

AU - Kwon, Jung Hyun

AU - Jang, Jeong Won

AU - Kim, Young Seok

AU - Kim, Tae Hun

AU - Jeon, Yong Sun

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Background/Aims: We analyzed the incidence of change of Barcelona Clinic Liver Cancer (BCLC) stage after add-on Primovist-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer stage 0 or A as determined by liver dynamic computed tomography (LDCT). Methods: A total of 166 patients enrolled prospectively between August 2012 and December 2014 were retrospectively analyzed. The rates of stage change after Primovist-enhanced MRI and the treatment finally adopted in patients with stage change were evaluated. Results: Of the 166 patients, 24 (18.6%) had truly new HCCs. Forty-six (27.7%) and 120 (72.3%) patients had BCLC stages 0 and A, respectively, before Primovist-enhanced MRI, but after Primovist-enhanced MRI, 28 (16.9%), 134 (80.7%), and 4 (2.4%) patients had BCLC stages 0, A, and B, respectively. Tumor stage changed in 22 (13.3%) patients, from 0 to A (18, 39.1%) or A to B (4, 3.3%). Conclusions: Add-on Primovist-enhanced magnetic resonance imaging can change BCLC stage with 13.3% in patients with BCLC 0 or A staged HCC, as determined by LDCT. J. Surg. Oncol. 2016;114:106–111.

AB - Background/Aims: We analyzed the incidence of change of Barcelona Clinic Liver Cancer (BCLC) stage after add-on Primovist-enhanced magnetic resonance imaging (MRI) in hepatocellular carcinoma (HCC) patients with Barcelona Clinic Liver Cancer stage 0 or A as determined by liver dynamic computed tomography (LDCT). Methods: A total of 166 patients enrolled prospectively between August 2012 and December 2014 were retrospectively analyzed. The rates of stage change after Primovist-enhanced MRI and the treatment finally adopted in patients with stage change were evaluated. Results: Of the 166 patients, 24 (18.6%) had truly new HCCs. Forty-six (27.7%) and 120 (72.3%) patients had BCLC stages 0 and A, respectively, before Primovist-enhanced MRI, but after Primovist-enhanced MRI, 28 (16.9%), 134 (80.7%), and 4 (2.4%) patients had BCLC stages 0, A, and B, respectively. Tumor stage changed in 22 (13.3%) patients, from 0 to A (18, 39.1%) or A to B (4, 3.3%). Conclusions: Add-on Primovist-enhanced magnetic resonance imaging can change BCLC stage with 13.3% in patients with BCLC 0 or A staged HCC, as determined by LDCT. J. Surg. Oncol. 2016;114:106–111.

KW - Barcelona clinic liver cancer

KW - hepatocellular carcinoma

KW - liver dynamic computed tomography

KW - primovist-enhanced magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=84976587401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976587401&partnerID=8YFLogxK

U2 - 10.1002/jso.24272

DO - 10.1002/jso.24272

M3 - Article

VL - 114

SP - 106

EP - 111

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 1

ER -